(RTTNews) - Sandoz Group AG (SDZ.SW, SDZNY), a pharmaceutical company focused on affordable medicines, on Friday announced a collaboration with mAbxience for a proposed emicizumab biosimilar. The financial terms of the agreement were not disclosed. Under the agreement, the company will have exclusive global commercialization rights for the biosimilar, excluding Argentina, Uruguay and Paraguay. mAbxience will be responsible for development and manufacturing of the proposed biosimilar. The reference medicine, Hemlibra, has a global market worth an estimated $5.7 billion. The collaboration expands its biosimilar pipeline to 40 assets and marks its first haemophilia biosimilar. On Thursday, Sandoz Group AG closed trading 3.29% higher at CHF 67.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。